- Advertisement -
A new drug for a type of brain cancer, called IDH-mutant low-grade glioma, was approved this month by the U.S. Food and Drug Administration—a promising treatment that stemmed from a genetic discovery made at the Johns Hopkins Cancer Center 16…

